DOI: https://doi.org/10.22263/2312-4156.2021.1.99
Avseiko M.V., Yarantseva N.D.
Chemical method for disposal of pharmaceutical waste of angiotensin-converting-enzyme inhibitor group
Belarusian State Medical University, Minsk, Republic of Belarus
Vestnik VGMU. 2021;20(1):99-110.
Abstract.
Objectives. To develop a method for chemical neutralization of pharmaceutical waste, as well as to assess its effectiveness and environmental safety.
Material and methods. The substances of captopril, lisinopril, enalapril, perindopril and ramipril were used as samples for testing the proposed disposal method. The chemical inactivation of drugs pharmacophores was carried out. The structure of the products obtained in the course of destruction has been established experimentally, and the efficiency of waste neutralization has been proved by the instrumental method of analysis – giant Raman spectroscopy. The toxicity of the initial compounds, as well as the structures obtained during destruction was determined based on the calculation of the semi-lethal dose (LD50) for rats on oral administration using the GUSAR Rat acute toxity computer simulation software package. The calculation of the partition coefficient in the octanol-water system (logPow) for the analyzed substances was carried out using the Molinspiration program.
Results. After carrying out the destruction reactions of the analyzed substances, there were no peaks in the spectra at frequencies characteristic of the carboxyl group, which confirms the effectiveness of the chemical method for disposing drugs. Ecotoxicological characteristics, such as the value of the semi-lethal dose and the partition coefficient in the octanol-water system, of degradation products also have more favorable values in comparison with the initial substances.
Conclusions. The possibility to use the chemical method for the disposal of pharmaceutical waste of the drugs group inhibiting angiotensin-converting-enzyme has been proved.
Key words: pharmaceutical waste, disposal, environmental safety, captopril, lisinopril, enalapril, perindopril, ramipril.
References
1. Mendis S, Puska P, Norrving B, red; Vsemir org zdravookhraneniia. World Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland; 2013. 155 р. (In Russ.)
2. On establishing a list of medicines sold without a prescription: postanovlenie M-va zdravookhraneniia Resp Belarus', 10 apr 2019 g, № 27. Nats tsentr pravovoi inform. Resp. Belarus'. Pravo.by [Elektronnyi resurs]: Nats pravovoi Internet-portal Resp Belarus'. Rezhim dostupa: https://pravo.by/document/?guid=12551&p0=W21934175&p1=1. Data dostupa: 03.02.2021. (In Russ.)
3. Pharmaceuticals and Environment. Available from: https://www.janusinfo.se/environment. [Accessed 03th Fev 2021].
4. Glushko AA, Chiryapkin AS, Chiryapkin VS, Murtuzalieva AM, Polkovnikova YuA. Development of a technique for modeling the interaction of biologically active substances with the active center of an angiotensin-converting enzyme. Farmatsiia Farmakologiia. 2017;5(5):487-503. (In Russ.)
5. Wang Z, Zhang S, Jin H, Wang W, Huo J, Zhou L, et al. Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based pharmacophore generation. Eur J Med Chem. 2011 Aug;46(8):3428-33. doi: http://dx.doi.org/10.1016/j.ejmech.2011.05.007
6. Watermeyer JM, Kröger WL, O'Neill HG, Sewell BT, Sturrock ED. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of Lisinopril. Biochem J. 2010 Apr;428(1):67-74. doi: http://dx.doi.org/10.1042/BJ20100056.
7. Tzakos AG, Gerothanassis IP. Domain-Selective Ligand-Binding Modes and Atomic Level Pharmacophore Refinement in Angiotensin I Converting Enzyme (ACE) Inhibitors. Chembiochem. 2005 Jun;6(6):1089-103. doi: http://dx.doi.org/10.1002/cbic.200400386
8. Rella M, Rushworth CA, Guy JL, Turner AJ, Langer T, Jackson RM. Structure-Based Pharmacophore Design and Virtual Screening for Novel Angiotensin Converting Enzyme 2 Inhibitors. J Chem Inf Model. 2006 Mar-Apr;46(2):708-16. doi: http://dx.doi.org/10.1021/ci0503614
9. Bandarenka HV, Girel KV, Zavatski SA, Panarin A, Terekhov SN. Progress in the development of SERS-active substrates based on metal-coated porous silicon. Materials (Basel). 2018 May 21;11(5):852. doi: http://dx.doi.org/10.3390/ma11050852
10. GusarOnline. Available from: http://www.way2drug.com/gusar/acutoxpredict.html. [Accessed 03th Fev 2021].
11. Andreeva EP, Raevskiy OA. Calculation of lipophilicity of organic compounds based on structural similarity and molecular physicochemical descriptors. Khim-Farmatsevt Zhurn. 2009;43(5):28-32. (In Russ.)
12. Molinspiration Cheminformatics. Available from: https://www.molinspiration.com/. [Accessed 03th Fev 2021].
13. Socrates G. Infrared and Raman characteristic group frequencies: tables and charts. London; England: John Wiley & Sons Ltd; 2001. 362 p.
14. Xi W, Shrestha BK, Haes AJ. Promoting Intra- and Intermolecular Interactions in Surface-Enhanced Raman Scattering. Anal Chem. 2018 Jan;90(1):128-143. doi: http://dx.doi.org/10.1021/acs.analchem.7b04225
Information about authors:
Avseiko M.V. – senior lecturer of the Chair of Pharmaceutical Chemistry, Belarusian State Medical University;
Yarantseva N.D. – Candidate of Pharmaceutical Sciences, associate professor, head of the Chair of Pharmaceutical Chemistry, Belarusian State Medical University.
Correspondence address: Republic of Belarus, 220116, Minsk, 83 Dzerzhinskogo ave., Belarusian State Medical University, Chair of Pharmaceutical Chemistry. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Natalia D. Yarantseva.
